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Background: Gastric cancer (GC) remains to have a poor prognosis via diverse process of cancer progression.
Dihydropyrimidinase-like 3 (DPYSL3) is a cell adhesion molecule that has been reported to be involved in the
metastatic process of tumor cells. The aim of this study was to identify a novel clinically-relevant biomarker of GC.
Methods: Expression analysis of DPYSL3 mRNA and protein levels was conducted using GC cell lines and 238 pairs of
surgically resected gastric tissues. Correlations between expression status of DPYSL3 and clinicopathological parameters
were investigated.
Results: DPYSL3 mRNA expression levels positively correlated with those of potentially interacting genes (VEGF, FAK
and EZR) in GC cell lines. GC tissues from tumors with distant metastases (stage IV cancer) showed elevated expression
levels of DPYSL3 mRNA. The DPYSL3 staining intensity in immunochemical staining was consistent with the mRNA
expression patterns in GC tissues. High DPYSL3 mRNA expression in GCs was significantly associated with more
malignant phenotypes and was an independent prognostic factor. Moreover, patients with high DPYSL3 mRNA
expression had a significantly shorter recurrence free survival after curative resection. In subgroup analysis based on
tumor histology, similar tendency was observed between patients with differentiated and undifferentiated GCs.
Conclusions: Expression status of DPYSL3 in GC tissues may represent a promising biomarker for the malignant
behavior of GC.
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Gastric cancer (GC) is the second leading cause of global
cancer mortality, accounting for 700,000 deaths annually
[1,2]. More than 70% of countries worldwide have a
mortality-to-incidence ratio greater than 0.8, suggesting
that prevention of late presentation and modified treat-
ment strategies are required to improve clinical out-
comes [3]. In particular, distant metastases including
peritoneal dissemination have been recognized as im-
portant prognostic determinants for GC patients [4,5].
Identifying genes relevant to the malignant behavior of
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unless otherwise stated.identifying high-risk patients and proposing novel mo-
lecular targets [6].
Recently, technological advances such as microarrays and
next-generation sequencing have allowed for the exhaustive
genomic characterization of malignancies, enhancing our
understanding of cancer initiation and progression [7-9].
With these techniques, numerous genetic and epigenetic al-
terations relevant to gastric carcinogenesis and GC progres-
sion have been reported [10]. However, understanding the
clinical significance of individual genes remains insufficient,
despite the accumulating array data.
Dihydropyrimidinase-like 3 (DPYSL3) is a cell-adhesion
molecule [11,12] and actively expressed in normal tissues
of cardiac myocytes, brain, pineal body, retina and smooth
muscle, and moderately expressed in various tissues in-
cluding gastric tissues [13]. DPYSL3 has been reported
to be involved in the metastatic process of tumor cellstd. This is an Open Access article distributed under the terms of the Creative
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analyses of DPYSL3 in prostate cancer and found that
DPYSL3 is a metastasis suppressor that is inversely associ-
ated with the expression of vascular endothelial growth
factor (VEGF) [14]. In contrast, Kawahara et al. reported
that DPYSL3 facilitates pancreatic cancer cell metastasis
via a strong interaction with other cell adhesion factors,
including ezrin (EZR), focal adhesion kinase (FAK) and
c-SRC [15]. Thus, DPYSL3 has attracted attention as a
metastatic modulator; however, the role of DPYSL3 ex-
pression in GC initiation and progression has not been
investigated.
Here, we focused on DPYSL3 as a potential facilitator
of malignant behavior in GC. The aim of this study was




This study conformed to the ethical guidelines of the
World Medical Association Declaration of Helsinki‐Ethical
Principles for Medical Research Involving Human Subjects
and has been approved by the Institutional Review Board
of Nagoya University, Japan. Written informed consent for
usage of clinical samples and data, as required by the insti-
tutional review board, was obtained from all patients.
Sample collection
Ten GC cell lines (H111, KATOIII, MKN1, MKN28,
MKN45, MKN74, NUGC2, NUGC3, NUGC4 and SC-6-
LCK) were obtained from the American Type Culture
Collection (Manassas, VA, USA) or Tohoku University,
Japan and cultured in RPMI-1640 medium supplemented
with 10% fetal bovine serum in 5% CO2 at 37°C. Primary
GC tissues and corresponding normal adjacent tissues
were collected from 238 patients undergoing gastric re-
section for GC without neoadjuvant therapy at Nagoya
University Hospital between 2001 and 2012. The collected
tissue samples were immediately flash-frozen in liquid ni-
trogen and stored at −80°C until RNA extraction. Approxi-
mately 5 mm2 was extracted from each tumor sample,
avoiding necrotic tissue by gross observation and only sam-
ples confirmed to comprise more than 80% tumor compo-
nents by H&E staining were included in this study.
Corresponding normal adjacent gastric mucosa samples
were obtained from the same patient and were collected >
5 cm from the tumor edge [16]. The specimens were clas-
sified histologically using the 7th edition of the Union for
International Cancer Control (UICC) classification [17].
To evaluate whether the expression status of DPYSL3
differed by tumor histology, patients were categorized into
two histological subtypes; differentiated (papillary, well dif-
ferentiated and moderately differentiated adenocarcinoma)
and undifferentiated (poorly differentiated adenocarcinoma,signet ring cell and mucinous carcinoma) tumors. Since
2006, adjuvant chemotherapy using S-1 (an oral fluori-
nated pyrimidine) has been applied to all UICC stage II–
IV GC patients unless contraindicated by the patient’s
condition [18,19].
Expression analysis of DPYSL3 mRNA
DPYSL3 mRNA expression levels of 10 GC cell lines and
238 primary GC tissues and corresponding normal adja-
cent tissues were analyzed through quantitative real-time
reverse-transcription polymerase chain reaction (qRT-
PCR) with an ABI StepOnePlus Real-Time PCR System
(Perkin-Elmer, Applied Biosystems) as described previously
[20,21]. The primer sequences used in this study are listed
in Additional file 1: Table S1. In clinical samples, mean ex-
pression level of DPYSL3 mRNA were compared between
GC tissues and corresponding normal adjacent tissues.
Additionally, expression level of DPYSL3 mRNA in GCs
was compared with each patient subgroup based on UICC
stage to investigate the oncological role of DPYSL3.
Expression of genes potentially interacting with DPYSL3
The expression status of VEGF, EZR, FAK and c-SRC,
which have previously been reported to be genes that
potentially interact with DPYSL3 [14,15], was evaluated
in GC cell lines through qRT-PCR. Primers specific for
VEGF, EZR, FAK and c-SRC are listed in Additional file 1:
Table S1.
Immunochemical staining
DPYSL3 protein localization was determined by immuno-
chemical staining using 54 representative formalin-fixed
and paraffin-embedded sections of well-preserved GC tis-
sue as described previously [22,23] with a mouse mono-
clonal antibody against DPYSL3 (LS-C133161, LifeSpan
BioSciences, Seattle, WA, USA) diluted 1:150 in antibody
diluent (Dako, Glostrup, Denmark). Staining patterns were
compared between GCs and the corresponding normal
adjacent tissues, and the intensity of DPYSL3 protein
expression was graded depending on the percentage
of stained cells as follows: no staining, minimal (<20%);
focal (20 – 60%); and diffuse (>60%) [24,25]. To avoid sub-
jectivity, the specimens were randomized and coded be-
fore analysis by two independent observers blinded to
the status of the samples. Each observer evaluated all
specimens at least twice to minimize intra-observer
variation [26].
Evaluation of clinical significance of DPYSL3 expression
Patients were stratified into two groups divided by the me-
dian value of DPYSL3 mRNA expression level in cancerous
tissues of the all analyzed patients; high DPYSL3 expres-
sion (higher than the median value) and low DPYSL3
expression (the median value or lower). Correlations
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clinicopathological parameters were evaluated. Outcome
analyses including disease specific survival rate, recurrence
free survival rate and multivariate analysis were performed
in 169 patients who underwent curative surgery (i.e. stage
I - III). Additionally, the prognostic impact of DPYSL3
mRNA expression was assessed in each patient subgroup
based on tumor differentiation.
Statistical analyses
The relative mRNA expression levels (DPYSL3/GAPDH)
between the two groups were analyzed using the Mann–
Whitney U test. The strength of a correlation between
two variables was assessed by the Spearman's rank cor-
relation coefficient. The χ2 test was used to analyze the
association between the expression status of DPYSL3Figure 1 Expression profile of GC cell lines. (A) Expression status of DPY
mRNA expression in GC cell lines was observed. Error bars indicated standa
between the mRNA expression levels of DPYSL3 and those of VEGF, FAK, EZand clinicopathological parameters. Disease specific and
recurrence free survival rates were calculated using the
Kaplan–Meier method, and the difference in survival
curves was analyzed using the log-rank test. We per-
formed multivariable regression analysis to detect prog-
nostic factors using the Cox proportional hazards model,
and variables with a P value of < 0.05 were entered into
the final model. All statistical analyses were performed
using JMP 10 software (SAS Institute Inc., Cary, NC,
USA). P < 0.05 was considered significant.
Results
Expression of DPYSL3 and potentially interacting genes in
GC cell lines
The relative mRNA expression levels of DPYSL3 and its
potential interacting genes in GC cell lines are shownSL3 and potentially interacting genes in GC cell lines. Differential
rd deviation among three biological replicates. (B) Correlative analysis
R and c-SRC.
Figure 2 Expression status of DPYSL3 in clinical specimens.
(A) GC tissues showed higher mean expression levels of DPYSL3
mRNA than corresponding normal adjacent tissues. (B) After
subdividing patients according to UICC staging, GC tissues from
patients with stage IV GC showed the highest DPYSL3 mRNA
expression levels compared with corresponding normal adjacent
tissues and those from patients with stage I-III GC. NS,
not significant.
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expression level of DPYSL3 and other genes among GC
cell lines. DPYSL3 expression levels positively correlated
with those of VEGF, FAK and EZR, while no interaction
was observed with c-SRC (Figure 1B).Figure 3 Detection of DPYSL3 protein. (A) Representative cases of each
magnification). (B) A positive correlation was observed between the expresPatient characteristics
The patient ages ranged from 20 to 84 years (65.3 ±
11.7 years, mean ± standard deviation), and the male:fe-
male ratio was 179:59. Pathologically, 139 patients were
diagnosed with undifferentiated GC and 99 with differ-
entiated GC. According to the 7th edition of the UICC
classification, 58, 40, 71 and 69 patients were in stages I,
II, III and IV, respectively. Sixty of the 69 stage IV pa-
tients were diagnosed as stage IV due to positive peri-
toneal lavage cytology, localized peritoneal metastasis or
distant lymph node metastasis including para-aortic lymph
nodes. Eight patients in stage IV had synchronous liver
metastasis one had lung metastasis, and they underwent
gastrectomy with the purpose of controlling tumor bleed-
ing or obstruction to the passage of food.
Expression status of DPYSL3 mRNA in 238 clinical GC
samples
Elevation of the mean expression level of DPYSL3 mRNA
was observed in GC tissues compared with the corre-
sponding normal adjacent tissues (Figure 2A). When sub-
dividing patients by UICC stage, DPYSL3 expression
levels were significantly higher in stage IV patients than in
stage I-III patients, indicating that DPYSL3 may promote
distant metastasis (Figure 2B).
Detection of DPYSL3 protein
Representative cases with each staining grade in GC tis-
sues are shown in Figure 3A. Diffuse staining of DPYSL3
protein in the cytoplasm of cancerous cells was ob-
served, whereas cells in the adjacent normal adjacentDPYSL3 staining intensity; no staining, minimal, focal and diffuse (400×
sion level of DPYSL3 mRNA and the staining intensity in GC tissues.
Table 1 Association between expression level of DPYSL3









< 65 year 51 49







≤ 5 93 98




≤ 37 95 99
> 37 24 20
Tumor location 0.769
Entire 12 8
Upper third 24 27
Middle third 37 35
Lower third 46 49
Tumor size (mm) 0.090
< 50 48 61
≥ 50 71 58





Well differentiated 4 10
Moderately differentiated 33 48
Poorly differentiated 74 56











Infiltrative growth type <0.001*
Invasive growth 55 28
Table 1 Association between expression level of DPYSL3
mRNA and clinicopathological parameters in 238 patients
(Continued)
Expansive growth 64 90
Lymph node metastasis <0.001*
Absent 32 57
Present 87 62




I - III 77 92
IV 42 27
Abbreviations: UICC Union for International Cancer Control. *Statistically
significant (P < 0.05).
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terns of DPYSL3 protein detected by IHC were consist-
ent with the qRT-PCR data. When grading the staining
intensity of the cancerous cells, patient numbers 8, 19,
15 and 12 were categorized as no staining, minimal,
focal and diffuse, respectively. A positive correlatin be-
tween the DPYSL3 staining grade and mRNA expression
levels in GC tissues was confirmed (Figure 3B).
Prognostic impact of expression status of DPYSL3 in
gastric tissues
Correlations between expression status of DPYSL3 mRNA
and clinicopathological parameters were evaluated in
238 patients with GC. High expression level of DPYSL3
mRNA in GCs was significantly associated with more ag-
gressive phenotype including pT4, invasive growth, lymph
node metastasis, positive peritoneal lavage cytology, and
UICC stage IV, and but not tumor location (Table 1).
Next, outcome analysis was carried out for 169 patients
who underwent curative surgery. Patients with high ex-
pression level of DPYSL3 mRNA in GCs (n = 84) were
more likely to have a shorter disease specific survival than
those with low expression level of DPYSL3 mRNA (n = 85;
the 5-year survival rates were 61% and 77%, respectively,
P = 0.010; Figure 4A). Multivariate analysis identified high
expression level of DPYSL3 mRNA in GCs as an inde-
pendent prognostic factor (Table 2). Moreover, high
expression level of DPYSL3 mRNA in GCs was signifi-
cantly associated with shortened recurrence free survival
(the 2-year survival rates were 67% in high expression
group and 84% in low expression group, respectively, P =
0.015; Figure 4B).
Subgroup analysis based on tumor differentiation
The prognostic impact of DPYSL3 expression was evaluated
in each patients subgroups classified by tumor differentiation.
Figure 4 Prognostic impact of DPYSL3 mRNA expression in GC patients. (A) The high DPYSL3 mRNA expression group had significantly
shorter disease specific survival than the low expression group. (B) Recurrence free survival was significantly shortened in the high DPYSL3 mRNA
expression group. (C) Curves comparing the disease specific survival of patient groups categorized by expression level of DPYSL3 mRNA in each
tumor differentiation.
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only in patients with differentiated GCs, similar tendency
was observed between survival curves of patients with dif-
ferentiated and undifferentiated GCs.
Discussion
DPYSL3, located on 5q32 and encoding a 62-kDa protein
[11], has been gaining attention as a metastasis modulator
[14,15]. Interestingly, conflicting results have been reported
in prostate and pancreatic cancer, implying that DPYSL3
has a diversity of functions among malignancies. In pros-
tate cancer, the expression of both DPYSL3 mRNA and
protein was inversely associated with lymph node metasta-
sis and VEGF expression, and forced DPYSL3 expressionin cell lines decreased metastasis in a mouse metastatic
model [14]. Alternatively, DPYSL3 promoted adhesion and
migration in pancreatic cancer cells in vitro as well as me-
tastasis in vivo via activation of other cell adhesion genes
[15]. In this study, the association between DPYSL3 ex-
pression and malignant behavior of GC was investigated.
First, the transcriptional status of DPYSL3 and poten-
tial interacting genes were evaluated in GC cell lines.
The expression of DPYSL3 mRNA was heterogeneous
in each GC cell line, and it showed a significant correl-
ation with known tumor promoting factors (VEGF, FAK
and EZR) [27-29]. These results indicated that DPYSL3
may be associated with the activation of cancer cell
proliferation and metastasis, as is the case with pancreatic
Table 2 Prognostic factors for disease specific survival in 169 patients who underwent curative surgery
Variable n Univariate Multivariate
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age (≥65) 97 1.38 0.73 – 2.70 0.327
Gender (male) 128 1.27 0.60 – 2.49 0.517
Tumor location (distal) 107 0.42 0.22 – 0.78 0.006 0.53 0.27 – 1.05 0.067
Carcinoembryonic antigen (>5 ng/ml) 27 1.71 0.73 – 3.56 0.202
Carbohydrate antigen 19–9 (>37 IU/ml) 23 2.33 0.99 – 4.90 0.054
Tumor size (≥50 mm) 76 3.02 1.54 – 6.35 0.001 2.06 0.98 – 4.57 0.056
Tumor depth (pT4, UICC) 55 2.82 1.50 – 5.39 0.001 1.09 0.52 – 2.32 0.815
Tumor differentiation (undifferentiated) 89 1.79 0.93 – 3.60 0.081
Lymphatic involvement 137 5.70 1.74 – 35.2 0.002 1.12 0.14 – 6.12 0.905
Vessel invasion 83 4.10 2.02 – 9.20 <0.001 2.93 1.31 – 7.52 0.008*
Invasive growth 41 2.51 1.31 – 4.73 0.006 1.39 0.64 – 3.00 0.404
Lymph node metastasis 86 8.70 3.71 – 25.5 <0.001 4.01 1.40 – 14.6 0.008*
Expression of DPYSL-3 mRNA (high) 84 2.36 1.22 – 4.72 0.010 2.22 1.14 – 4.49 0.019*
*Statistically significant in multivariable analysis. GC, gastric cancer; CI, confidence interval; UICC, Union for International Cancer Control.
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an expression analysis using surgical gastric tissues was
conducted and provided important findings. DPYSL3
expression levels in patients with distant metastasis
(stage IV) were significantly elevated compared with
patients with localized GC (stage I-III), implying that
DPYSL3 upregulation was an important determinant step
in the GC progression. Consequently, high expression
level of DPYSL3 mRNA in GC tissues was strongly associ-
ated with shortened survival and was identified as an inde-
pendent prognostic factor. These results indicated that
DPYSL3 upregulation may contribute to GC progression
rather than carcinogenesis. Because DPYSL3 has been re-
ported to play a role in cell adhesion and be a metastatic
modulator, the correlations between expression status of
DPYSL3 and metastasis were analyzed. Patients with up-
regulated DPYSL3 had a significantly higher prevalence of
lymph node metastasis, overall distant metastasis and
peritoneal dissemination, indicating that DPYSL3 is a me-
tastasis facilitator of GC, and high expression of DPYSL3
may predict the metastatic behavior associated with an in-
vasive GC phenotype. Data from the expression analysis
of interacting genes also support the hypothesis that
DPYSL3 has an oncogenic function in GC as with pancre-
atic cancer [15].
Because GC is considered a biologically heterogeneous
disease, and genetic backgrounds can differ according to
GC subtype [30-33], a subgroup analysis was conducted.
Expression status of DPYSL3 was similar across tumor lo-
cation (entire, upper third, middle third and lower third).
In addition, patients with high expression level of DPYSL3
mRNA in GCs tended to have a shorter survival both in
patient groups of differentiated and undifferentiated GCs.These findings indicated that DPYSL3 acts similarly in all
types of GC.
Although further investigation will be necessary to clar-
ify the underlying molecular mechanism that connects
DPYSL3 upregulation directly to malignant behavior, our
findings may offer valuable insight for the specific man-
agement of GC patients. Taken together, DPYSL3 can be
used in clinical practice as follows: 1) DPYSL3 expression
levels in the biopsy tissue obtained using endoscopic sur-
veillance samples may identify patients in need of inten-
sive systemic treatment; and 2) DPYSL3 expression levels
in the surgical specimen may be useful for the prediction
of an adverse prognosis, also aiding in determining an ap-
propriate therapeutic strategy.
Conclusion
DPYSL3 acts as a facilitator of malignant behavior of
GC. High expression level of DPYSL3 in GC tissues may
represent a promising biomarker for the malignant be-
havior of GC.Additional file
Additional file 1: Table S1. Primers and annealing temperature.
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